Biomerica, Inc. (BMRA)
After hours:
| Previous Close | 4.5100 |
| Open | 4.6000 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1100 |
| Day's Range | 4.4500 - 4.6750 |
| 52 Week Range | 3.3000 - 8.1500 |
| Volume | |
| Avg. Volume | 219,142 |
| Market Cap | 59.119M |
| Beta (5Y Monthly) | -0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4490 |
| Earnings Date | Apr. 12, 2022 - Apr. 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- GlobeNewswire
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter InFoods® IBS endpoint trial is complete, topline trial results expected by the end of January IRVINE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its second
- GlobeNewswire
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021. All figures in this release are approximate due to the preliminary nature of this announcement. For the second quarter of fiscal 2022, ended November 30, 2021, Biomer
- Simply Wall St.
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
The share price of Biomerica, Inc. ( NASDAQ:BMRA ) has increased significantly over the past few years. However, the...
